Compare Abbott Laboratories (ABT) vs Verizon Communications Inc (VZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Verizon Communications Inc — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while Verizon Communications Inc trades at $42.9 (market cap $177.84B). The key difference: Abbott Laboratories and Verizon Communications Inc are close in size by market cap, and Verizon Communications Inc pays the higher dividend (6.64%). Which is the better fit depends on your goals.
| ABT | VZ | |
|---|---|---|
Market Cap | $166.94B | $177.84B |
Sector | Health | Media |
52-Week High | $136.62 | $51.38 |
52-Week Low | $82.57 | $38.40 |
Enterprise Value | $193.69B | $365.34B |
Dividend Yield | 2.63% | 6.64% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Verizon (VZ) trades at $42.59, up 0.07% on the day, with a bearish technical signal but attractive valuation metrics including a P/E of 10.26 and dividend yield near 6.7%. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.28 exceeding expectations. The company maintains strong cash flow from operations at $37.14 billion in 2025, supporting its dividend payments. However, the stock has underperformed the wireless industry over the past year, declining 0.4% versus sector growth of 102.8% (Zacks Investment Research, 2026-07-07).
Outlook: Verizon offers value and income appeal with a low P/E and high dividend, but faces competitive pressures from SpaceX's Starlink and technical bearishness. Risks include high debt levels and industry disruption. Analyst consensus price target is $50.25, suggesting 18% upside potential, with 37% buy ratings indicating cautious optimism amid challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
